$-0.45 EPS Expected for TRACON Pharmaceuticals, Inc. (TCON); Jupiter Fund Management Plc (LON:JUP) Covered By 2 Bulls

February 17, 2018 - By Pete Kolinski

Analysts expect TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to report $-0.45 EPS on February, 27.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.45 EPS. After having $0.07 EPS previously, TRACON Pharmaceuticals, Inc.’s analysts see -742.86% EPS growth. The stock decreased 1.12% or $0.02 during the last trading session, reaching $2.2. About 377,852 shares traded or 114.09% up from the average. TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) has declined 52.06% since February 17, 2017 and is downtrending. It has underperformed by 68.76% the S&P500.

Among 19 analysts covering Jupiter Fund Management plc (LON:JUP), 2 have Buy rating, 3 Sell and 14 Hold. Therefore 11% are positive. Jupiter Fund Management plc had 172 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Jupiter Fund Management Plc (LON:JUP) has “Add” rating given on Thursday, January 12 by Numis Securities. JP Morgan maintained the shares of JUP in report on Friday, January 12 with “Neutral” rating. The company was maintained on Monday, July 10 by RBC Capital Markets. Peel Hunt maintained the stock with “Add” rating in Friday, February 24 report. The firm earned “Buy” rating on Thursday, January 14 by Panmure Gordon. The firm earned “Neutral” rating on Tuesday, October 11 by BNP Paribas. JP Morgan maintained it with “Overweight” rating and GBX 475 target in Friday, July 31 report. Barclays Capital maintained Jupiter Fund Management Plc (LON:JUP) on Tuesday, March 1 with “Overweight” rating. The firm has “Add” rating given on Tuesday, May 24 by Numis Securities. The stock has “Buy” rating by Numis Securities on Wednesday, July 27. See Jupiter Fund Management Plc (LON:JUP) latest ratings:

01/02/2018 Broker: Numis Securities Rating: Hold Old Target: GBX 595.00 New Target: GBX 595.00 Maintain
31/01/2018 Broker: Credit Suisse Rating: Underperform Old Target: GBX 500.00 New Target: GBX 550.00 Maintain
12/01/2018 Broker: JP Morgan Rating: Neutral Old Target: GBX 600.00 New Target: GBX 600.00 Maintain
12/01/2018 Broker: Barclays Capital Rating: Equal Weight Old Target: GBX 585.00 New Target: GBX 600.00 Maintain
11/01/2018 Broker: Liberum Capital Rating: Buy Old Target: GBX 664.00 New Target: GBX 664.00 Maintain
11/01/2018 Broker: Shore Capital Rating: Hold Maintain
11/01/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 600.00 New Target: GBX 600.00 Downgrade
11/01/2018 Broker: Numis Securities Rating: Hold Old Target: GBX 595.00 New Target: GBX 595.00 Maintain
03/01/2018 Broker: Numis Securities Rating: Hold Old Target: GBX 590.00 New Target: GBX 595.00 Maintain
13/12/2017 Broker: JP Morgan Rating: Neutral Old Target: GBX 565.00 New Target: GBX 600.00 Maintain

Among 4 analysts covering Tracon Pharmaceuticals Inc (NASDAQ:TCON), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Tracon Pharmaceuticals Inc had 4 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Friday, September 4 by Zacks. The stock of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) earned “Buy” rating by Jefferies on Wednesday, December 21. The rating was initiated by TH Capital on Wednesday, July 29 with “Buy”. The firm has “Buy” rating by Roth Capital given on Wednesday, July 29.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration , and fibrotic diseases. The company has market cap of $38.53 million. The Company’s lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD. It currently has negative earnings. The company's other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>